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ABSTRACT 
The clean water crisis is a world and Indonesia issue.The hospital is a place of public service 
that plays an important role for maintaining the survival of human life.Consumption of 
antibiotics in hospitals causes potential contamination of residual antibiotics that will be mixed 
with wastewater.Regulations on hospital wastewater in Indonesia have not regulated the 
content of antibiotics.Antibiotics are resistant and persistent if they are in aquatic environments 
even in small concentrations. Hospital wastewater treatment system has not been designed 
process the antibiotics, so it needs to be developed alternative technology and solve the 
problem.This research was conducted for 1.5 years, sample using hospital wastewater type B 
in Palembang City used grab and composite sampling. Research design used a laboratory-scale 
design experiment to analyze the performance of Hybrid membrane (NF-RO) in treating 
antibiotics in hospital wastewater. Membrane performance calculation variables are 
rejection.Quantitative analysis showed a Ciprofloxacin level of 4.7 ppm and exceeded the 
prevailing standard quality in Europe (EC50<1 ppm).These results proved there is a correlation 
between the quantity of antibiotics with hospital wastewater become the potential pollutant 
agent in the water.The results of the study showed Hybrid membrane (NF-RO) performance 
reducing the levels of Ciprofloxacin antibiotics. The highest hybrid membrane (NF-RO) 
rejection was 98,31% (80 psi and 1,5 h) with Ciprofloxacin levels at retentate of 0,06 ppm and 
Rejection system was 98,56%. This result showed Hyrid membrane process is possible 
appliction in hospital to overcome the antibiotics resistance problems. 
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BACKGROUND 
The data which are released by the WWF world organization in the annual toxic chemical 
reports between 1930 to 2000 reveals that the production of chemicals as the causing of human 
activities increased from 1 million to 400 millions per year. Statical data which are published 
by Euro Statin 2013 showed that in the years of 2002 to 2011, more than 50% of the total 
production of chemicals produced the harmful compounds and 70% of the chemical had the 
significant environmental impacts. In addition, the human activities have resulted in the 
contamination of water sources with the highly toxic biological micropollutants such as viruses 
and bacteria (Xie, 2012; Periasamy and Sundaram, 2013; Sui et al., 2015).  
Verlicchi et al. (2015) and Tran et al. (2013) reported that some contaminant pollutants 
require the further attention and treatment due to the limited regulation and have typical waste 
characteristics of Pharmaceuticals and personal care products (PPCPs). PPCPs is categorized 
as the chemical substances used by humans and animals in the preventing of diseases, 
disinfectants, perfumes, lotions, and other personal needs. The study which was conducted by 
 
 
  
   
Bu et al. (2013) in China and Lea et al. (2012) in South Carolina explained the potential, 
sources, and impacts which were generated by PPCPs on the environment. PPCPs have the 
persistent and bioaccumulative properties as the residue in the environment and potentially 
affects the health and ecological impacts (Brausch dan Rand, 2011; Brausch et al., 2012; 
Daugton, 2013; Vasquez et al., 2014). 
Some residue which was detected including Analgesics/anti-inflammatories, Antibiotic, 
Cardiovascular pharmaceuticals(b-blockers/diuretics), Estrogens dan hormonal compounds, 
Psycho-stimulants, and Antiepileptic drug (Li et al., 2015).  Evgenidou et al., (2015) found that 
the Pharmaceuticals and personal care products (PPCPs) and prohibit drugs provided the 
negative impacts as the biotic and abiotic environmental through the derivative products of the 
transformation which was generated by the lack of knowledge, technology, and efficiency in 
the reducing of drugs. 
In general, the hospital activities obviously produce some residues of medicines 
including antibiotics. Currently, Antibiotics become the most important part of the treatment 
due to treating the human infection, Vasquez et al. (2015) reported the potential pollution of 
the biological wastes of hospital affects either direct and indirect effects on the human health. 
Hospital wastewater which is containing the chemicals and drugs is carcinogenic and genotoxic 
that can initiate the growth of cancer and genetic disorders (Cuong et al., 2013; Escher et al., 
2010; Orias and Perrodin, 2013; Sharma et al., 2015; Bayer et al., 2014).  
Hospitals as the one form of health services to the community in a variety of activities 
produce the wastewater that can be processed to minimize the impact before discharged into 
the water body. The ministry of health reported that in 2014 there were 2.410 hopitals in 
Indonesia. Furthermore, in South Sumatera, there were 55 hospitals where 27 hospitals were 
located in Palembang. Moreover, from the number of hospitals, it was estimated that the 
hospital could produce 376.089 tons per day and 48.985,70 tons per day of the solid waste and 
wastewater, respectively (Dhani and Yulinah, 2011).  
Bebianno and Rey (2015) concluded that the exposing of hospital wastewater in large 
quantities have a wide impact on the aquatic environment. Hamjinda et al. (2015) observed the 
characteristics of hospital wastewater with the research subjects of antibiotics compounds at 
seven hospitals in Bangkok and found several antibiotic compounds (Kuinolon, Ofloxacin, 
Levofloxacin, Norfloksasin, Siprofloksasin, Sulfametoksazol, and Norfloksasin) which have 
toxicity impacts to some microorganisms such as Chlorella vulgaris and Scenedesmus 
quadricauda), and Microcrustacean (Moina macrocopa). Kurniawan et al. (2017)  found 5 types 
of antibiotics (Ciprofloxacin, Lincomycin, Metronidazole, Netilmicin, 
Ofloxacin/Levofloxacin) in the hospital wastewater in Palembang, Indonesia. 
Kyzas et al. (2015) and Verlicchi et al. (2012b) found that the wastewater containing 
medicinal residues was very dangerous and toxic to humans and the environment. Furthermore, 
the trace number of micropollutant in parts per billion (ppb) or parts per trillion (ppt) in the 
drinking water have a detrimental effect on human health due to chronic properties (Huerta-
Fontela et al., 2010, Ratola et al., 2012, Nam et al., 2014). 
Hospital waste is all waste produced by hospital activities in solid, liquid, and gas forms. 
Hospital wastewater is all wastewater including stool derived from hospital activities that may 
contain microorganisms, toxic chemicals, and radioactive substances harmful to health 
(Kepmenkes RI No:1204/Menkes/SK/X/2004 about Hospital health environment 
requirements). Hospitals include the producers of hazardous and toxic waste from a specific 
source with D.277 codes (PP No.85,1999). Hospital activities produce solid, liquid, and gas 
wastes with distinctive characteristics with high organic content, suspended materials, 
relatively high amounts of fat and volume (Taylor and Senac, 2014). 
Wastewater treatment is a contaminant processing technology as a strategy to reduce the 
burden of upstream environmental pollution through wastewater treatment system. Wastewater 
 
 
  
   
treatment plant is an instrument that is generally a combination of three wastewater treatment 
processes including physical, mechanical-biological, and chemical process. The physical-
mechanical and chemical process is basically similar with the wastewater treatment to get the 
clean water in which the active sludge process is commonly used in the biological wastewater 
treatment (Jiang et al., 2013) 
In fact in the environment, WWTP still leaves a lot of problems and obstacles. The extent 
of the location of the instrumentation, and also the cost required for the installation or 
maintenance increase the cost of the hospital wastewater treatment process. furthermore, the 
generated effluent requires the further treatment thus consuming high energy and cost. Some 
studies were conducted by (Zorita et al., 2009;  Kosma et al., 2010; Behera et al., 2011; Deegan 
et al., 2011; Jelic et al., 2011; Gracia-Lor et al., 2012 reported that the sewage treatment plant 
owned by the hospital does not have the ability to reduce the content of medicines in 
wastewater. 
 
SOLUTION 
Chonova et al. (2016) reported that commonly the WWTP of the hospital was not 
designed to remediate the wastewater containing the drugs which most of the wastewater could 
release as the wastewater contained the drugs. It was shown by the specific characteristics 
which reported by Gracia-Lor et al. (2012) who conducted a research in Valencia, Spanyol. 
The results presented that the WWTP of hospital needs a specific plan to include some efforts 
to minimize the waste and wastewater treatment through the wastewater treatment plant. The 
characteristics of hospital wastewater containing the Pharmaceuticals and personal care 
products (PPCPs) is difficult to be reduced by common hospital wastewater treatment system 
(Rivera-utrilla et al., 2013). 
Membrane technology as one of the installations of sewage treatment unit has the 
promising development and progress. Membrane technology is mostly done in the process of 
separation and purification of drinking water  (Bodzek et al., 2012). Membranes have several 
advantages compared the conventional methods such as providing the continuous running 
process with low energy consumption, requiring no additional chemical and can run at low 
temperature, easy to scale up, requiring no extreme condition, varying of membrane material 
which easily adaptable and combined with other separation and treatment. (Kusumawatidan 
Tania, 2012). 
The use of membrane technology in the wastewater treatment process is relatively 
expensive compared to the active sludge because it requires some additional handling such as 
routine membrane cleaning, and replacing of membranes. If we use the long-term perspective 
with twenty-year wastewater treatment needs with the optimum wastewater effluent quality 
requirements, the cost required in the membrane technology is equal with the conventional 
activated sludge (Young et al., 2012).  
Madaeni, et al. (2015) explained that the membrane process offers the significant 
advantages due to operational simplicity, flexibility, cost-effectiveness, reliability, low energy 
consumption, good stability, environmental compatibility, easy to control, handling, and scale 
up with the operating conditions such as temperature, pressure, and pH. Furthermore, nano-
filtration and technology which use the pressure principle on the membrane called reverse 
osmosis are relatively new technology in the wastewater treatment system (Shon et al., 2013). 
Although the process uses relatively high operational and consumption costs, the process is the 
latest technology of filtration process to reduce the contaminant with high concentrations and 
has the challenge to be made on the contaminants with distinctive characteristics (Oller et al., 
2014). 
 
 
  
   
The membrane process using nanofiltration (nF) and reverse osmosis (RO) is 
increasingly used to produce high-quality water. Numerous studies have demonstrated the 
ability of nF-RO to remove the organic and inorganic contaminants including pharmaceutical 
wastewater (Kim et al., 2007; Radjenovic et al., 2008; Yangali and Quintanilla, 2008; Dolar et 
al., 2013: Kurniawan et al. 2016). Frederic and Yves (2014) and Alzahrani and Wahab (2014) 
reported that the new technology should be implemented in the hospital wastewater treatment 
because there were several micropollutants found in the treated wastewater.   
In the literature reviews, most of the hospital wastewater treatment in Indonesia use the 
activated sludge which is combined with the aerobic and anaerobic pond to remove the 
contaminant. However, the treatment does not have a pre-analysis and post-analysis to 
identification thepharmaceutical compounds releasing as the WWTP effluent because it was 
not necessary and the quality standard managed by the government does not regulate in detail 
which compound should be removed during the treatment. Prayitno et al. (2012) conducted a 
research about the quality of hospital wastewater in Malang and some study reports about the 
quality of wastewater in some hospitals in Indonesia (RSUD KeletJepara, RSUD Dr. 
Muhammad ZeinPainanSumbar, RS Permadi, RSU Prov. NTB, RSUP 
Dr.WahidinSudirohusodoSulsel, RS PKT Bontang, RSUP Persahabatan). The results showed 
that operator of wastewater only monitored the physics, chemistry, biology, and radioactivity 
aspects according to the hospital wastewater quality standard. 
Membrane technology might be a solution in hospital wastewater treatment and the 
development of membrane process can be combined (hybrid membrane) with the membrane 
method of nanofiltration and reverse osmosis (Singh, 2015). The nanofiltration process 
combined with reverse osmosis can separate the impurity components having characteristics 
containing the medicinal residue of 94% -100% (Dolar et al., 2012). The hybrid nF-RO is the 
latest technology which is not widely applied in hospital wastewater treatment. 
The sense of the process membrane through hybrid or integrated system is assembling a 
membrane processing process in an installation by combining one or more membrane process 
with or without conventional processes to improve the performance of treatment depending on 
the feed characteristics and products (Greenle et al., 2009). The hybrid system might reduce 
the operational costs and environmental pollution and enhance the efficiency of the treatment. 
U.S. Department of Energy (2016) showed that some economic advantages of hybrid 
membrane usage in clean wastewater treatment process shown below. 
a. Reduce the electricity cost through combining the hybrid process with more than 90 % of 
an advanced process of wastewater treatment  
b. Reduce 20% or more of the wastewater treatment cost 
c. Reduce 90% of carbon emission 
d. Reduce 94% of the contaminant in the wastewater  
Zakrzewska-Trznadel (2013) have conducted the advanced technologies through 
incorporate two membrane process using UF and RO membranes to treat radioactive 
wastewater from actinide partition.Plakas et al. (2012) reported that the hybrid nF-RO process 
could reduce pesticide wastewater. Abid et al. (2012) also performed the nF-RO process to 
remove the pollutant from the textile industry wastewater in Iraq and the results showed that 
the nF-RO could effectively remove 92.2%, 99.58, and 99.9% of the color, black, and blue 
dyes, respectively with the optimum condition of 65 mg/L of concentration, 39oC of feed 
temperature, and 8 bar of pressure. The results showed that the membrane technology had a 
higher reducing capacity with a lower effective cost. In addition, the study showed that the use 
of nF membranes in the removal of color waste from Iraq possessed the promising technology. 
 
 
 
 
  
   
METHOD OF IMPLEMENTATION 
Sampling 
In this study, the hospital wastewater was taken from the wastewater treatment plant in 
the first pond (primary pond) where all the hospital activities that produce the wastewater are 
flowed and collected in this pond. The first pond shaped beam with a size of 2.4 m x 1.9 m x 
4.0  with a capacity of 18.2 m3. The wastewater was taken using Vandorn Sampler (Fig.1) with 
a specific depth. The wastewater sampler should comply with the requirements which made of 
a material which does not affect and contaminate the sample, easy to clean, carry, and move 
the sample into the container bottle without any residual suspended material in it.  
 
 
 
Figure 1.Vandorn Sampler 
 
The sampling process is conducted into 3 steps which is preparation sampling, taking 
grab and composite, and packing. The sampling process refers to SNI 6989.59:2008 (water and 
wastewater-chapter 59: Wastewater sampling method). The sampling process was taken on 
Monday (26th – 31st of October 2016) at 10.00-11.00Western Indonesian Timezone at peak 
load capacity of wastewater treatment volume. The sampling process is taken at a time of 
moment at one particular location and a mixture of wastewater sample which is taken from 
different points over time with the same volumes (composite).  
The sample analysis was conducted by collecting the wastewater into the polyethylene 
bottle (Figure 2), and homogenized and divided into two or more parts of the sample. The 
sample was treated equally and analyzed in PT. Angler Bio Chem Laboratory, Surabaya 
(Akreditasi KAN LP-514-IDN, SNI ISO/IEC 17025:2008).  The sample containers (bottle) 
should comply the requirements of glass or polyethylene (PE) or polypropylene (PP) or 
ethylene (PTFE) or polyurethane or polytetrafluoroethylene (PTFE) which easily to be sealed, 
clean and free of contaminant, quite strong, and high stability. 
 
  
Figure 2.Polyetilen bottle 
 
 
  
   
Membrane design the hybrid process (NF-RO) 
The advanced process after the pretreatment process is a membrane block which is the 
producing of a membrane hybrid process (nF-RO). RO is commonly used in the post-treatment 
process due to the capacity to remove the dissolved ions, solids, and organic matters (Pandey 
et al., 2012). 
The design of the research process has 17 L/h of capacity with a commercial nF 
membrane (F11028, British Portacle-Water Quality USA) and RO (CSM Korea Model RO 
2012-100) equipped with housing membrane. The pipe is polyurethane tube with the pipe size 
on membrane block of 3/8 mm and block RO ¾ mm with the maximum working scale of 230 
psi and temperature 150oF. The process uses the RO pump with the maximum inlet pressure 
of 60 psi and outlet pressure of 110 psi with the normal flow rate of 1.8 LPM. In this step, the 
advanced pretreatment process is conducted. Figure 3 showed the design of hybrid membrane 
technology process. 
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Figure 3. the design of hybrid membrane technology process 
 
Description: 
1. Inlet tank 
Made of plastic material with a capacity of 300 L. The inlet tank is used as the membrane 
feed wastewater. 
2. Pomp 2 
It serves to drain the feed to the membrane hybrid process block. 
3. Filter of 10" 5 micron 
4. Filter of 10" 1 micron 
The 5 micron (DAI-05) and 1 micron (DAI-01) filter catridge serves to filter out the 
particles and other contaminants which still present in the feed. Temperature: 5-60 oC, 
Water Quality, USA Design. 
5. Granular Activated Carbon (GAC) 
Model GAC 933 RO Coconut Activated Carbon USA Technology, Degree of Nominal 
Filtration 5 micron, Design flow rate max : 1.5 GPM, Maximum temperature : 100 0F (38 
0C), Maximum pressure : 125 psi (8,6 bar), Minimum Pressure : 20 psi (1,4 bar). 
6. CTO Carbon Blok Filter 
Reduction ofGiardia, Cryptosporidium, Certsin, VOCs, Chlorine, Extra fine sediment, 
smell and taste. Pressure: 2 psi 1 GPM. Maximum operating temperature :  38 0C 
7. Pressure Gauge 
It serves to see the pressure of the water rate flow before entering the nF. 
8. Flow Meter  
It serves to see the process flow rate entering the nF. 
 
 
  
   
9. Booster Pump RO 
It serves as a water booster on RO with pressure of 60 psi with maximum pressure of 110 
psi, electric power: 48 volts dc 
10. Nanofiltration Membrane 
British Portacle, Ceramic, Tubular Device, Standard 2 x 10 inch Water Quality USA. 
Typical Flow Rate 45 PSI 1,3 GPM. Typical Flow Rate 3 Bar 5 LPM. 
11. Pressure Gauge 
It serves to see the water flow pressure entering the RO  
12. Flow Meter  
It serves to see the water flow rate entering the RO  
13. Reverse Osmosis 
Model RO 2012-100, 250C, pH 6,5-7, Membrane type Thin-Film Composite, Membrane 
material Polyamide (PA), Element Configuration Spiral Wound. 
14. Anti Flow 300 cc 
It has forms like a water sensor swithc which makes it suitable for connecting to the RO 
hose and has a food grade and function to deliver discharge water from RO membrane 
filtration. In addition, there is a one way dual advantage that blocks the direction of water 
opposite to the norla flow direction. This function makes the RO membrane unpolluted. 
15. Pressure Gauge 
It serves to see the water flow pressure exiting the RO (permeat). 
16. Flow Meter  
It serves to see the water flow rate exiting the RO (permeat) 
17. Post Carbon 
Material : Coconut Shell Activated Carbonwith the size of 10" and the use-lifetime of 3-4 
months. Design flow rate max: 1.9 LPM or 50 GPM. Maximum temperature: 100 0F (38 
0C). Minimum temperature: 35 0C. Maximum pressure: 125 psi (8,6 bar). 
18-21 Permeat container tank and concentrate 
 
 
Quantitative analysis of antibiotic levels in Hospital wastewater 
Samples from 2 liters of the sample were analyzed by the high-performance liquid 
chromatography (HPLC) Empower 3 Alliance Waters C 2695 to determine the concentration 
of Ciprofloxacin antibiotics before and after the treatment.  
The detection of contaminated wastewater which contents specific micropollutants 
especially drugs could be analyzed using HPLC (Ren et al., 2008; Dolar et al., 2013; Mendoza 
et al., 2015; Sabry et al., 2015). According to Ferrer and Thurman (2012), The use of High-
resolution Mass Spectroscopy (LC/Q-TOF/MS) with the principle of mass spectrometry allows 
the identification and characterization of over 100 drugs and metabolites in water sources at 
the smallest concentration in parts per trillion (ppt). That analysis provides the good sensitivity 
and selectivity in the identification of untrammeled antibiotics in low concentration in water 
samples.  
 
Research sample 
The sample which is used in the true experiment research is taken by the sampling 
process technique that refers to SNI 6989.59:2008 with grab and composite method at some 
points of retrieval (base, center, and surface of the pond). The wastewater sample was further 
homogenized and transferred into a temporary container. 
 
 
 
 
  
   
Hospital wastewater treatment system  
In 2016, the data from the health office department of Palembang city showed that there 
were 31 hospitals in Palembang consisting of 10 state-owned hospitals (31.25%) and 21 private 
hospitals (68.75%). From 10 of hospitals in palembang, only one hospital which is owned by 
the government of Palembang city which is the general hospital of Palembang region Bari. The 
other provincial government hospitals are Moh. Husin Hospital, Eye Hospital, etc. Hospitals 
are almost spread throughout the district of Palembang (Figure 4.1. Maps of the hospital's 
location in Palembang). The potential of hospitals in the producing of wastewater from the 
hospital activity can accumulate in the aquatic environment.  
 
 
Fig. 4.1 Maps of the hospital's location in Palembang 
 
The hospital wastewater could be generated from the bathrooms, washing room, kitchen, 
treatment room, polyclinic room, action room, laboratory room, delivery room, surgery room, 
morgue, etc, which generate the chemicals (toxic), infectious, and radioactive. The X hospital 
wastewater treatment system (Figure 4 and 5) uses a combination of integrated physic, 
chemical, biological process. The stages of X hospital wastewater treatment is shown as 
follows: 
1. Wastewater is first processed in thePrimary pondwith a tube size of 2.4 m x 1.9 m x 4.0 m 
with a value of ± 18,2 m3.The primary pond is wastewater storage pond of the first control 
or effluent basin after passing through the screening. 
2. The next stage is Equalisation pond with a tube sizing of 4.85 m x 3.95 m x 4 m with a 
volume of ± 76,6 m3. Equalisation pond serves as a wastewater discharge container that 
has variations of wastewater characteristics such as high pH from laundry, fat from the 
kitchen, and waste from the bathroom. 
 
 
  
   
3. Clarifier pond with a tube sizing of 4 m x 2 m x 4 m with a volume of ± 32 m3. Clarifier 
pond is a place to aerated the wastewater to provide the contact between the wastewater 
and air to assist the separation process between solid and water. 
4. Buffer pond serves as a temporary pond of wastewater before being processed into the 
Biodetox with a tube sizing of 4 m x 2,6 m x 2,1 m with a volume of ± 24 m3. Biodetox is 
made by a stainless material which has uniqueness in water flow and bacterial house design. 
5. Chlorination pondwith a tube sizing of 1,5 m x 1,5 m x 5 m with a volume of ±  3,1 m3. 
Chlorination pond is a place to add some dosages of chlorine that serves to reduce or kill 
the existing germs. 
6. Polishing pond with a  tube sizing of 3,45 m x 1,75 m x 4 m with a volume of ± 24,2 m3. 
Polishing pond is used as the the last sediment pond before entering the treated water pond.  
7. Treated water pond with a tube sizing of 0,97 m x 0,80 m x 4 m with a volume of ± 31 m3. 
Treated water pond is used as the temporary holding place of wastewater that has met the 
BMLC requirements. In addition, wastewater in the treated water pond will be screened. 
The filter serves to separate the suspended particles which have the fine particle size. Filter 
media comprised of 40 cm quartz sand, 15 cm fine pebbles, 15 cm rough pebbles, and 10 
cm activated carbon.The sediment from theClarifier pondandPolishing pondis storage in 
Sludge pond with a tube sizing of 2,3 m x 2 m x 4 m with a volume of ± 18,4 m3. Sludge 
pond uses the Airlift system. The processing product from sludge pond will be returned to 
the primary pond. 
 
 
 
 
Figure 4. The condition of Waste Water Treatment Equipment and Systems 
 
 
 
  
   
(1) Operator room (2) Underground gate 
 
(3) Biodetox 
 
(4) Biodetox  
Figure 5. Location of Wastewater Treatment  
 
The conventional wastewater treatment process produces several problems which 
become the negative impacts of derivatives on the environment within a certain period of time. 
The conventional WWTP (physic, chemical, and biological) do not have a convenient 
performance to remediate the hospital wastewater containing the drugs (Zorita et al., 2009;  
Kosma et al., 2010; Deegan et al., 2011; Jelic et al., 2011; Gracia-Lor et al., 2012). The 
alternative technology is needed to address the problem. The green aspect becomes the main 
focus in the designing a hospital wastewater treatment system. Membrane technology is an 
alternative solution that can be done to solve some problems that can not be solved by a 
conventional method. Furthermore, within 20 years in the improving of the quality of waste, 
the processing cost using membrane system will be similar with the processing cost using the 
conventional sludge (Young et al., 2012). Membrane hybrid process (nF-RO) could integrate 
the wastewater treatment system to provide the quality of the antibiotic effluent that is 
environmentally safe. 
 
The use of Antibiotics in the studied hospital 
 
The study was conducted in the X hospital which was the type B of the hospital. The 
primary data was collected through the time series method of retrieving data on the use of 
antibiotics in the period of the month or a certain period. All the data can be regarded as 
historical data or time series. X hospital refers to WHO (2004) regulation in the use and 
antibiotics criteria for patient and the criteria are: 
a. The use of antibiotics is adjusted for the disease indication 
 
 
  
   
b. The treatment is based on the individual complaints and accurate physical examination 
results 
c. The appropriate dosing is done through various criteria (depending on age, weight, and 
chronological disease) 
d. The antibiotics treatment is performed using appropriate intervals of time, distance, and 
administration of drugs was adjusted to prescribed use rules, and in certain cases requiring 
the administration of drug within a certain period of time. 
e. The given-drug should be effective with a guaranteed quality, avoiding the expired drug 
administration and do not in accordance with the type of complaint of the illness of 
patients. 
f. The type of medicine is easy to get with the affordable prices 
g. The minimizing the dose to reduce the side effects and drug allergies. 
 
In general, the use of antibiotics in X hospital can be seen in Table 1. Table 1 showed the 
information on qualitative uses of antibiotics in X hospital in the period of July to September 
2016. All the antibiotics are given to the inpatients and outpatients of X hospital through the 
oral and injection treatments. 
 
Table 1.   Qualitative Information on Antibiotic Usage at RS X Palembang July-September 
2016 Period 
 
Antibiotics Medicines Use Group 
Amikacin Amikacin, Amiosin Injection Aminoglycosides 
Amoxicillin Amoxicillin, Amoxsan Syrup, Tablet Beta-lactam 
Amoxicillin dan 
Clavulanat 
Co Amoxiclav, Capsinat Syrup, Tablet Beta-lactam 
Azitromycin Azomax, Infimycin, 
Zibramax, Zistic 
Syrup, 
Tablet, 
Injection 
Macrolide 
Ampicillin dan 
Sulbactam 
Bactesyn Injection and 
Tablet 
Beta-lactam 
Cefadroxyl Cefradoxyl, Cefat, 
Renasistin 
Syrup, 
Kapsul 
Cephalosporins 
Cefixime Cefixime, Fixacep, 
Nucef, Starcef 
Syrup, 
Kapsul, Drop 
Cephalosporins 
Cefuroxime Anbacim Injection Cephalosporins 
Cefotaxime Cefotaxime, Biocef, 
Kalfoxim 
Injection Cephalosporins 
Cefoperazone Cefoperazone, Cefoject Injection Cephalosporins 
Ceftriaxone Broadced Injection Cephalosporins 
Ceftazidime Ceftazidime, Ceftum, 
Zibac 
Injection Cephalosporins 
Ceftizoxime Ceftizoxime Injection Cephalosporins 
Ceftriaxone Ceftriaxone, Elpicef Injection Cephalosporins 
Clindamycin Clindamycin Capsule Clindamycin 
Cotrimoxazol Cotrimoxazol Syrup, Tablet Sulfonamides 
Ciprofloxacin Ciprofloxacin, Baquinor, 
Renator 
Tablet Quinolones 
Doxixyclin Doxixyclin Capsule Tetracycline 
Erytromycin Erytromycin, Erysanbe Tablet, Syrup Macrolide 
Kanamycin Kanamycin Injection Aminoglycosides 
Levofloxacin Cravit, Volequin Tablet, 
Infusion 
Quinolones 
Lincomycin Lincomycin Capsule, 
Syrup 
Lincosamide 
Metronidazole Farnat Infusion Nitroimedazole 
 
 
  
   
Meropenem Merem, Merofen, 
Meropenem 
Injection Beta-lactam 
Netilmicin Netromycin Injection Aminoglycosides 
Ofloxacin Ofloxacin, Pharflox Tablet Quinolones 
Primadex Primadex Tablet, Syrup Sulfonamides 
Tetracycline Tetracycline, Tetrasanbe Capsule Tetracycline 
Thiamphenicol Thiamphenicol, 
Biothicol 
Capsule Thiamphenicol 
 
Antibiotics are anti-bacterial substances which are produced by various species of 
microorganisms (bacteria, fungi, and actinomycota) that can suppress the growth and or kill 
other microorganisms. According to Hadi (2009), 30%-80% of patients in Indonesia do not use 
the antibiotics based on the indication experienced by the patients whereas in the other 
developed country 13-37% of all hospitalized patients get either single or double antibiotics.  
Nowadays, the use of irrational antibiotics is common in both the developed and developing 
country. 
Based on the legislation, X hospital has a hospital pharmacy installation which has the 
leadership of a pharmacist who is assisted by several pharmacists. A pharmacy installation is a 
place of the facility for the operation which is responsible for all work and pharmaceutical 
services including antibiotics. In X hospital, the use of antibiotics is classified based on the 
mechanism of action of the use of antibiotics. The classification is shown below. 
1. Beta-lactam, Cephalosporins, Lincosamide, Nitroimedazole classare treated for inhibiting 
the synthesis or demaging the cell wall of bacteria or protozoa. 
2. Aminoglycosides, Thiamphenicol, Tetracycline, Macrolide, Clindamycin,class are used to 
modify or inhibit the protein synthesis. 
3. Sulfonamides type is used to inhibit the essential enzyms in the folic metabolism,  
4. Quinolones type is used to synthesise or metabolizes the nucleic acid. 
 
The high number uses of antibiotics is not accompanied by the cultures and habits that are not 
good in the handling of antibiotic residue. The residue of the use of antibiotics in the form of 
fluids especially from the vials and infusion in medical service activities is often discharged 
into the pipeline which eventually empties into the primary pond and then mixed with the 
wastewater from all hospital activities. The small number of antibiotics in the wastewater could 
be dangerous for the environment. From the field study, there was a flow pattern of wastewater 
in the sewage system in the hospital WWTP (Figure 6). The flow pattern chart shows that there 
is a potential of antibiotics remnants from the hospital activities that mix with hospital 
wastewater from all hospital activity systems. 
 
Hybrid membrane process 
In the first step in hybrid membrane process (Fig. 6), an operation test is performed to determine 
the performance of the membrane system in general by using incoming distilled water feed into 
the processing system with various operating pressures and run for 30 minutes for each 
operating pressure. The test results on each of the membrane performance variables can be seen 
in Table 2. 
 
 
 
  
   
 
Figure 6.The design result of hybrid membrane process 
 
Table 2.the variable of the performance hybrid membrane (nF-RO) 
 
Variables Operation performance 
Minimum Pressure 60 psi 
Maximum Pressure 80 psi 
The average of Volume Permeat ± 13 L NF and 9 L RO 
The average of flow rate ± 16 L/h NF and 8 L/h RO 
The average ofFlux ± 8 L/m2.h NF and 7 L/m2 .h 
The average of WRP ± 45% NF and 50% RO 
The average of TMP ± < 2 psi from the operation pressure 
 
In this study, the design process is different from the previous research. Beier et al., 
(2010) makes the design of hospital wastewater with 250 L as the treatment capacity with the 
biometric membrane bioreactor (MBR) and two stage-nanofiltration (nF) commercial and one 
stage-reverse osmosis (RO) commercial with flow cross flow system and high pressure (60 
bar). In the other study, Dolar et. al., (2012) have built the 700 L/day of hybrid membrane 
process using coagulation pretreatment using FeCl3. The process used two stage-Nanofiltration 
(NF) Dow/FilmTec NF270 and NF90 Polyamide and one stage-reverse osmosis (RO) extra 
low-energy Dow/FilmTec XLE Polyamide, for each type cross flow. 
The results of quantitative analysis prove that there was a ciprofloxacin antibiotic 
detected with the concentration of 4.7 ppm. There was a correlation between the level of 
antibiotic use in hospital activity with the antibiotic content which was found in the hospital 
wastewater. The levels of antibiotics use in hospital X at the time of sampling in March 2017 
can be seen in Figure 7 to 9. 
 
 
  
   
 
Fig. 7. The use of vial of infusion antibiotics in X hospital per March 2017 
 
Fig. 8. The use of capsule/tablet antibiotics in X hospital per March 2017 
 
Fig. 9. The use of syrup/drop antibiotics in X hospital per March 2017 
 
Membrane Rejection 
 
Membrane rejection is performed to determine the membrane performance in the 
removing a contaminant contained in the feed. The research uses to types of commercial 
membranes namely NF ceramics and RO composite polyamide. The hybrid membrane is 
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operated under the same condition by first passing through the nF and terminated on the RO 
process. The feed through NF is the result of ineffective pretreatment process in the reducing 
of Ciprofloxacin levels while the feed into RO is a permeate feed of NF.  
The process is run for 2 hours in each pressure (60, 70, 80 psi) with the sampling of 
Ciprofloxacin levels every 30 minutes. The result of NF and RO rejection coefficient 
calculation is shown in Table 3. The determination of Ciprofloxacin concentration is 
conducted using standard curve equations and AUC values of the curves of each process 
resulting in the obtained-CIP concentration of each stage of the process for the use of 
wastewater sample. 
 
Table 3.NF-RO CIP X hospital wastewater rejection 
 
Code Pressure (atm) t (hour) Cf (ppm) Cp (ppm) R (%) R System(%) 
NF - 1 
4,082 
0,5 4,79 3,86 19,36 
98,55 
RO - 1 0,5 3,86 0,06 98,21 
NF - 2 1 4,79 3,88 18,89 
98,09 
RO - 2 1 3,88 0,09 97,64 
NF - 3 1,5 4,79 4,04 15,51 
98,19 
RO - 3 1,5 4,04 0,086 97,86 
NF - 4 2 4,79 3,96 17,24 
98,11 
RO - 4 2 3,96 0,09 97,72 
NF - 5 
4,763 
0,5 4,79 3,90 18,42 
98,17 
RO - 5 0,5 3,90 0,08 97,76 
NF - 6 1 4,79 3,86 19,37 
98,38 
RO - 6 1 3,86 0,07 97,99 
NF - 7 1,5 4,79 3,96 17,30 
97,95 
RO - 7 1,5 3,96 0,09 97,53 
NF - 8 2 4,79 3,97 17,03 
98,04 
RO - 8 2 3,97 0,09 97,64 
NF - 9 
5,443 
0,5 4,79 4,07 14,98 
98,53 
RO - 9 0,5 4,07 0,07 98,27 
NF - 10 1 4,79 4,07 14,99 
98,44 
RO - 10 1 4,07 0,07 98,16 
NF - 11 1,5 4,79 4,07 14,88 
98,56 
RO - 11 1,5 4,07 0,06 98,31 
NF - 12 2 4,79 4,08 14,78 
97,55 
RO - 12 2 4,08 0,11 97,12 
 
The ciprofloxacin rejection through nF using hospital wastewater feeds has the highest 
performance at the first operational (60 psi, 4.08 atm, 1.2 hours) with the yield performance 
of 19.36%. The increasing of processing time showed the decreasing of rejection. The 
advanced process using RO process produces the highest rejection of 98.31% (80 psi; 5,44 
atm, 1,5 hour). The comparison of these results indicates that the ceramic nF membrane is 
less effective in the reducing of ciprofloxacin level but the RO polyamide composite is highly 
effective in the reducing of ciprofloxacin levels. This result showed that there can be no 
antibiotic rejection process in one step membran process. 
 
 
  
   
The small ceramic membrane rejection is affected by the nF membrane pore size and 
non-maximal ceramic raw material in the filtration process with feed containing the organic 
matter and microorganism whereas the polyamide composite has the better capacity 
(Charcosset, 2012). The study showed that the nF-RO process has the highest rejection 
performance of 98.56% (80 psi, 1.5 hours). The performance of the nF-RO system has 
decreased the value of rejection along with the length of the process. This fact justifies the 
theory of concentration on the membrane surface where the length of operation time could 
increase the concentration of membrane at its pore resulting the cloves pores.  
The research which is conducted by Beier et al. (2010) showed the percentage of 
rejection of ciprofloxacin on nF and RO which were 97.02% and 98.15%, respectively. In 
addition, Dollar et al (2012) reported that the rejection has the below the LOD value. In this 
study, the RO rejection shows the better yield which results in 98.31% (0.068 ppm) and the 
final concentration is also below the LOD (0.18 ppm). On the other hand, this study uses the 
simpler operational condition compared to the previous studies which are more complex 
(Table 4 shows the comparison of the current and previous research).  
European legislation regulates the maximum ciprofloxacin antibiotic content with 
EC50 ≤ 1 ppm in the environment. The results also showed that the final result of 
ciprofloxacin concentration process was below 1 ppm which is fulfilled the rules of European 
legislation. According to Stuart et al. (2012), hospital waste is one source of contaminants in 
the waters. The ability of membrane rejection which capable to reduce the CIP in the 
wastewater contribute significantly to the clean water conservation program by increasing 
the volume of clean water that people can still consume. 
Ciprofloxacin in the hospital activities is widely used in the form of infusions and 
capsules/tablets. Ciprofloxacin which is detected in the hospital wastewater comes from the 
residual infusion of patients discharged through the hospital waste stream and mixed in the 
primary pond. Tabel 4 showed some antibiotics findings especially Ciprofloxacin in the 
hospital wastewater. According to Certificate of Analyzed (COA), Ciprofloxacin is issued by 
Dexa Medica (Attachment file 6) and it has the physical properties dissolved in water even in 
the relatively small amount. The nature of the solubility might determine the amount of 
concentration of the substance present in the hospital wastewater. 
 
Table 4.The research history of the ciprofloxacin content in the hospital wastewater  
 
Researcher 
Sampling 
Location 
Ciprofloxacin Contents Legislation 
Europe 
Beier et al., 2010 German 7,2 mg/L  
 
EC50 ≤ 1 
mg/L 
Dolar et al., 2012 Croasia 17,48 mg/L 
Santos et al., 2013 Spain 3673 ng/L 
Varela, et al., 2014 Portugal 0,88 mg/L 
Tuc et al., 2016 France 11 mg/L 
Asia 
Hamjinda et al., 2015 Thailand 9,8 mg/L  
- Ashfaq et al., 2016 Pakistan 18 mg/L 
This study  (2017) Indonesia 4,7 mg/L  
 
The legislation in Asia particularly Indonesia on the antibiotic content in hospital wastewater 
has not included these parameters while the legislation is applicable in the European countries 
through European Union Law (Eur-Lex). Girardi et al. (2011) state that the content of 
Ciprofloxacin antibiotics in the environment has EC50 ≤ 1 ppm as the threshold and the 
concentration equal or above the threshold generate the very toxic compound when exposed to 
 
 
  
   
the aquatic organism. In addition, the contaminated ciprofloxacin will be very toxic if exposed 
to the soil organism. The results of the study in Table 4.6 related to Ciprofloxacin antibiotics 
contained in the hospital wastewater and found that the most concentration has exceeded the 
existing legislation in Europe. An effort should be made to reduce the concentration of 
ciprofloxacin using membrane technology by studying the membrane performance. 
 
CONCLUSION 
The WWTP system of X hospital uses the primary pond-equalisation pond-clarifier pond-
buffer pond-chlorination pond-polishing pond-treated water pond equipped with Biodetox. 
One of the major problems of the hospital wastewater treatment is undesigned for the 
processing of antibiotic component. The highest final rejection was owned by an RO membrane 
of 98.3% (80 psi at 1.5 h) with a 0.06 ppm concentration of Ciprofloxacin at retentate (EC50 
<1 ppm) as the main variable for measuring membrane hybrid process (nF-RO) in the 
decreasing of antibiotic content in Hospital wastewater. Hybrid membrane (nF-RO) as a system 
showed a rejection of 98.56% removing ciprofloxacin in wastewater. The hybrid membrane 
can be applied to overcome the problem of antibiotic resistance. 
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